Abstract | OBJECTIVE: DESIGN: Double-blind, randomized, placebo-controlled trial. SETTING: University outpatient clinic. PATIENT(S): The study cohort consisted of 50 obese women (body mass index [BMI] ≥ 27 kg/m(2)) and 60 nonobese patients (BMI <27 kg/m(2)), mean age was 27.7 ± 4.0 SD years. INTERVENTION(S): Randomization to receive metformin or placebo for 3 months. MAIN OUTCOME MEASURE(S): Serum levels of 8-OHdG before and after medical treatment. RESULT(S): The levels of 8-OHdG were equal at baseline in the placebo and metformin groups. Obese women had higher baseline serum concentrations of 8-OHdG. Levels of 8-OHdG were statistically significantly reduced with metformin treatment, especially in obese patients with polycystic ovary syndrome. This study was a secondary subanalysis of a previously conducted prospective multicenter, randomized, placebo-controlled study on the effects of metformin on miscarriage, pregnancy, and miscarriage rates. CONCLUSION(S): CLINICAL TRIAL REGISTRATION NUMBER: NCT00994812.
|
Authors | Henri Sova, Ulla Puistola, Laure Morin-Papunen, Peeter Karihtala |
Journal | Fertility and sterility
(Fertil Steril)
Vol. 99
Issue 2
Pg. 593-8
(Feb 2013)
ISSN: 1556-5653 [Electronic] United States |
PMID | 23122829
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- 8-hydroxy-2'-deoxyadenosine
- Biomarkers
- Deoxyadenosines
- Hypoglycemic Agents
- Metformin
|
Topics |
- Adult
- Biomarkers
(blood)
- Deoxyadenosines
(blood)
- Double-Blind Method
- Down-Regulation
(drug effects)
- Female
- Humans
- Hypoglycemic Agents
- Metformin
(therapeutic use)
- Polycystic Ovary Syndrome
(blood, drug therapy)
- Treatment Outcome
|